RxDoctor Payments Data

Jalal Baig, MD

Hematology & Oncology · Gurnee, ILNPI 1740647437

Payments from drug & device makers

$3,603in general payments, 2019–2025

Across 85 payments — averaging $42.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novartis$543
  • Gilead$266
  • Amgen$202
  • Seagen Inc.$85
  • Pharmacyclics LLC, An Abbvie Company$82
  • plus $638 from 19 others

What the payments were for

  • Consulting fees$1,66546%
  • Food & beverage$1,84851%
  • Education$902%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,603 in reported general payments places this provider in the 40th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$489,707
Medicare patients
298
Services billed
22,274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide12$182,117
BrukinsaZanubrutinib12$181,150
Abiraterone Acetate35$65,686
EliquisApixaban51$36,441
Ondansetron Hcl38$1,115
Dexamethasone37$974
Anastrozole47$603
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen27$472
Prochlorperazine Maleate25$470
Hydroxyurea31$461
Gabapentin23$134
Lorazepam14$123
Prednisone31$115
Famotidine20$111
Levothyroxine Sodium15$110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$65$36,44151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 580 hematology & oncology providers in Illinois.

Other hematology & oncology in Gurnee

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →